Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Scienze Radiologiche ed Ematologiche. Università Cattolica Del Sacro Cuore, Rome, Italy.
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Clin Oncol (R Coll Radiol). 2024 Aug;36(8):e269-e281. doi: 10.1016/j.clon.2024.03.003. Epub 2024 Mar 15.
Radiomics is a promising tool for the development of quantitative biomarkers to support clinical decision-making. It has been shown to improve the prediction of response to treatment and outcome in different settings, particularly in the field of radiation oncology by optimising the dose delivery solutions and reducing the rate of radiation-induced side effects, leading to a fully personalised approach. Despite the promising results offered by radiomics at each of these stages, standardised methodologies, reproducibility and interpretability of results are still lacking, limiting the potential clinical impact of these tools. In this review, we briefly describe the principles of radiomics and the most relevant applications of radiomics at each stage of cancer management in the framework of radiation oncology. Furthermore, the integration of radiomics into clinical decision support systems is analysed, defining the challenges and offering possible solutions for translating radiomics into a clinically applicable tool.
放射组学是一种有前途的工具，可用于开发定量生物标志物，以支持临床决策。已经证明，它可以通过优化剂量传递解决方案和降低放射性副作用的发生率，从而在不同的环境中，特别是在放射肿瘤学领域，改善对治疗反应和结果的预测，从而实现完全个性化的方法。尽管放射组学在这些阶段都提供了有希望的结果，但标准化方法、结果的可重复性和可解释性仍然缺乏，限制了这些工具的潜在临床影响。在这篇综述中，我们简要描述了放射组学的原理以及放射组学在放射肿瘤学框架下癌症管理各个阶段的最相关应用。此外，还分析了将放射组学纳入临床决策支持系统，定义了将放射组学转化为临床应用工具所面临的挑战，并提供了可能的解决方案。
